Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain

NCT01571362 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01571362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01571362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
June 30, 2013
Enrollment
410 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

analgesia, chronic pain, low back pain